WO2002029097A3 - Procedes - Google Patents

Procedes Download PDF

Info

Publication number
WO2002029097A3
WO2002029097A3 PCT/GB2001/004332 GB0104332W WO0229097A3 WO 2002029097 A3 WO2002029097 A3 WO 2002029097A3 GB 0104332 W GB0104332 W GB 0104332W WO 0229097 A3 WO0229097 A3 WO 0229097A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymorphisms
gene
gpr10
methods relating
human
Prior art date
Application number
PCT/GB2001/004332
Other languages
English (en)
Other versions
WO2002029097A2 (fr
Inventor
John Charles Brennand
Carl Thomas Montague
Stephen O'rahilly
Sumit Bhattacharyya
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
John Charles Brennand
Carl Thomas Montague
Stephen O'rahilly
Sumit Bhattacharyya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, John Charles Brennand, Carl Thomas Montague, Stephen O'rahilly, Sumit Bhattacharyya filed Critical Astrazeneca Ab
Priority to AU2001292027A priority Critical patent/AU2001292027A1/en
Publication of WO2002029097A2 publication Critical patent/WO2002029097A2/fr
Publication of WO2002029097A3 publication Critical patent/WO2002029097A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des polymorphismes dans le gène GPR10 humain et de nouveaux peptides alléliques correspondants codés ainsi. L'invention concerne également des procédés et des matériaux permettant d'analyser la variation allélique dans le gène GPR10 humain et l'utilisation du polymorphisme GPR10 dans le diagnostic et le traitement de maladies dans lesquelles la modulation de l'activité GPR10 pourrait présenter un avantage thérapeutique, en particulier dans les états maladifs associés à la régulation du métabolisme comme l'obésité, les diabètes non insulino-dépendants, le syndrome de résistance à l'insuline, la dislipidémie et l'athérosclérose.
PCT/GB2001/004332 2000-10-06 2001-09-28 Procedes WO2002029097A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001292027A AU2001292027A1 (en) 2000-10-06 2001-09-28 Methods relating to polymorphisms in the human gpr10 gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0024510.0A GB0024510D0 (en) 2000-10-06 2000-10-06 Methods
GB0024510.0 2000-10-06

Publications (2)

Publication Number Publication Date
WO2002029097A2 WO2002029097A2 (fr) 2002-04-11
WO2002029097A3 true WO2002029097A3 (fr) 2003-08-28

Family

ID=9900796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/004332 WO2002029097A2 (fr) 2000-10-06 2001-09-28 Procedes

Country Status (3)

Country Link
AU (1) AU2001292027A1 (fr)
GB (1) GB0024510D0 (fr)
WO (1) WO2002029097A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080099A2 (fr) * 2002-03-26 2003-10-02 Bayer Healthcare Ag Diagnostics et traitements de maladies associees au recepteur 10 couple aux proteines g (gpr10)
WO2004048610A1 (fr) * 2002-11-28 2004-06-10 Universidad De Barcelona Methodes diagnostiques et therapeutiques pour le diabete et l'obesite

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017641A1 (fr) * 1998-09-22 2000-03-30 Millennium Pharmaceuticals, Inc. Utilisation de la gpr10 comme cible pour l'identification de composes influant sur le poids
WO2001009182A1 (fr) * 1999-08-03 2001-02-08 Oy Juvantia Pharma Ltd. Peptide de liberation de la prolactine et methode destinee a la regulation de fonctions autonomes et au traitement de la douleur

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017641A1 (fr) * 1998-09-22 2000-03-30 Millennium Pharmaceuticals, Inc. Utilisation de la gpr10 comme cible pour l'identification de composes influant sur le poids
WO2001009182A1 (fr) * 1999-08-03 2001-02-08 Oy Juvantia Pharma Ltd. Peptide de liberation de la prolactine et methode destinee a la regulation de fonctions autonomes et au traitement de la douleur

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 23 December 2002 (2002-12-23), XP002233363, retrieved from WWW.NCBI.NLM.NIH.GOV/ Database accession no. NM_004248, NM_005287 *
DATABASE GENBANK [online] 7 May 1999 (1999-05-07), XP002233362, retrieved from WWW.NCBI.NLM.NIH.GOV/ Database accession no. NM_004248 *
HINUMA ET AL: "A prolactin-releasing peptide in the brain", NATURE, MACMILLAN JOURNALS LTD, vol. 393, 21 May 1998 (1998-05-21), London, GB, pages 272-272 - 275, XP002077456 *
MARCHESE A ET AL: "CLONING AND CHROMOSOMAL MAPPING OF THREE NOVEL GENES, GPR9 GPR10, AND GPR14, ENCODING RECEPTORS RELATED TO INTERLEUKIN 8, NEUROPEPTIDE Y, AND SOMATOSTATIN RECEPTORS", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 29, no. 2, 20 September 1995 (1995-09-20), pages 335 - 344, XP000673922, ISSN: 0888-7543 *
SCHAFER A J ET AL: "DNA VARIATION AND THE FUTURE OF HUMAN GENETICS", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 16, January 1998 (1998-01-01), pages 33 - 39, XP000890128, ISSN: 1087-0156 *
STADEL J M ET AL: "Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 18, no. 11, 1 November 1997 (1997-11-01), pages 430 - 437, XP004099345, ISSN: 0165-6147 *

Also Published As

Publication number Publication date
GB0024510D0 (en) 2000-11-22
WO2002029097A2 (fr) 2002-04-11
AU2001292027A1 (en) 2002-04-15

Similar Documents

Publication Publication Date Title
WO2006063704A3 (fr) Polymorphisme a simple nucleotide (snp)
WO2003038123A3 (fr) Procede de traitement du diabete et conditions apparentees basees sur des polymorphismes dans le gene tcf1
WO2006042152A3 (fr) Produits pharmaceutiques a base de polypeptides intestinaux vasoactifs
WO2002100341A3 (fr) Composes destines au traitement de troubles metaboliques
WO2005011680A8 (fr) Utilisation d'antagonistes du recepteur de l'angiotensine ii, en particulier de telmisartan, pour augmenter la sensibilite a l'insuline
PT2527315E (pt) Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
WO2005077072A3 (fr) Polypeptides hybrides presentant des proprietes pouvant etre choisies
WO2004041165A3 (fr) Composes destines au traitement de troubles metaboliques
AU2002330215A1 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
AU2003252182A1 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
EP1186672A3 (fr) Polymorphismes dans le gène humain du transporteur d'anion organique (OATP-C)
EP2096120A3 (fr) Utilisation de produits à protéines sécrétées pour empêcher et traiter les maladies pancréatiques et/ou l'obésité et/ou un syndrome métabolique
WO2007070355A3 (fr) Produits botaniques anti-inflammatoires pour le traitement du syndrome metabolique et du diabete
WO2000069901A3 (fr) Nouvelles proteines a action insulinoide utilisees dans le traitement du diabete
PT1648483E (pt) Composição para tratamento e/ou prevenção da resistência à insulina
WO2006063703A8 (fr) Polymorphisme a simple nucleotide (snp)
WO2004069194A3 (fr) Compositions et procedes pour traiter le diabete
WO2002029097A3 (fr) Procedes
WO2003104381A3 (fr) Procedes
WO2000047721A3 (fr) Procedes visant a induire des cellules souches positives insuliniques
EP1199372A3 (fr) Polymorphismes du gène humain P2X7
WO2003082283A3 (fr) Compositions pharmaceutiques contenant une combinaison de principes actifs et procedes permettant de les utiliser
WO2003014391A3 (fr) Procede
WO2002072888A3 (fr) Composes chimiques
WO2002083944A3 (fr) Composes chimiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP